Orchestra BioMed (NASDAQ:OBIO) Director Jason Aryeh Purchases 8,971 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Jason Aryeh purchased 8,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $3.90 per share, for a total transaction of $34,986.90. Following the purchase, the director directly owned 117,453 shares in the company, valued at $458,066.70. This represents a 8.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Orchestra BioMed Price Performance

NASDAQ OBIO opened at $3.98 on Tuesday. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. Orchestra BioMed Holdings, Inc. has a 1 year low of $2.20 and a 1 year high of $5.42. The company has a market cap of $238.32 million, a PE ratio of -4.10 and a beta of 0.52. The stock’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $4.27.

Orchestra BioMed (NASDAQ:OBIO) last announced its earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. On average, analysts predict that Orchestra BioMed Holdings, Inc. will post -1.62 EPS for the current year.

Hedge Funds Weigh In On Orchestra BioMed

A number of hedge funds have recently modified their holdings of OBIO. Bank of America Corp DE raised its holdings in shares of Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after acquiring an additional 7,036 shares in the last quarter. Creative Planning purchased a new position in Orchestra BioMed in the second quarter valued at about $40,000. XTX Topco Ltd acquired a new position in Orchestra BioMed in the 2nd quarter worth about $45,000. Marshall Wace LLP acquired a new position in Orchestra BioMed in the 2nd quarter worth about $133,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $118,000. 53.20% of the stock is owned by institutional investors and hedge funds.

Orchestra BioMed News Summary

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Director Eric Fain bought 20,000 shares at $4.13 each, a $82,600 purchase that increased his stake by 27.89%. Insider buying can signal management confidence in the company’s outlook. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while raising several earnings estimates for 2026 and 2027. The higher forecast for Q2 2026 EPS and improved longer-term projections suggest analysts see somewhat better fundamentals ahead. Article Title
• Neutral Sentiment: HC Wainwright’s updated estimates still show losses for every quarter and year covered, so the company remains unprofitable in the near term despite the upgrades. Article Title
• Neutral Sentiment: Recent analyst commentary remains mixed overall, with some firms maintaining bullish ratings while others have downgraded the stock, keeping sentiment somewhat split. Article Title

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wall Street Zen cut shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings cut Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Orchestra BioMed in a research report on Thursday, May 14th. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, March 12th. Finally, Barclays raised their price objective on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Orchestra BioMed currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.